PlainRecalls
FDA Drug Moderate Class II Ongoing

Chantix (varenicline)Tablets, Contains: 1 Starting Week (0.5 mg* x 11 tablets), 3 Continuing Weeks (1 mg x 42 tablets), Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, Made in Ireland, NDC 0069-0471-03.

Reported: August 11, 2021 Initiated: June 9, 2021 #D-0700-2021

Product Description

Chantix (varenicline)Tablets, Contains: 1 Starting Week (0.5 mg* x 11 tablets), 3 Continuing Weeks (1 mg x 42 tablets), Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, Made in Ireland, NDC 0069-0471-03.

Reason for Recall

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

Details

Recalling Firm
Pfizer Inc.
Units Affected
350,985 cartons
Distribution
Nationwide
Location
New York, NY

Frequently Asked Questions

What product was recalled?
Chantix (varenicline)Tablets, Contains: 1 Starting Week (0.5 mg* x 11 tablets), 3 Continuing Weeks (1 mg x 42 tablets), Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, Made in Ireland, NDC 0069-0471-03.. Recalled by Pfizer Inc.. Units affected: 350,985 cartons.
Why was this product recalled?
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit
Which agency issued this recall?
This recall was issued by the FDA Drug on August 11, 2021. Severity: Moderate. Recall number: D-0700-2021.